<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32627229</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>88</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>The Distinct Traits of the UNC13A Polymorphism in Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>796</StartPage><EndPage>806</EndPage><MedlinePgn>796-806</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.25841</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The rs12608932 single nucleotide polymorphism in UNC13A is associated with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) susceptibility, and may underlie differences in treatment response. We aimed to characterize the clinical, cognitive, behavioral, and neuroimaging phenotype of UNC13A in patients with ALS.</AbstractText><AbstractText Label="METHODS">We included 2,216 patients with ALS without a C9orf72 mutation to identify clinical characteristics associated with the UNC13A polymorphism. A subcohort of 428 patients with ALS was used to study cognitive and behavioral profiles, and 375 patients to study neuroimaging characteristics. Associations were analyzed under an additive genetic model.</AbstractText><AbstractText Label="RESULTS">Genotyping rs12608932 resulted in 854 A/A, 988 A/C, and 374 C/C genotypes. The C allele was associated with a higher age at symptom onset (median years A/A 63.5, A/C 65.6, and C/C 65.5; p &lt;&#x2009;0.001), more frequent bulbar onset (A/A 29.6%, A/C 31.8%, and C/C 43.1%; p &lt;&#x2009;0.001), higher incidences of ALS-FTD (A/A 4.3%, A/C 5.2%, and C/C 9.5%; p =&#x2009;0.003), lower forced vital capacity at diagnosis (median percentage A/A 92.0, A/C 90.0, and C/C 86.5; p &lt;&#x2009;0.001), and a shorter survival (median in months A/A 33.3, A.C 30.7, and C/C 26.6; p &lt;&#x2009;0.001). UNC13A was associated with lower scores on ALS-specific cognition tests (means A/A 79.5, A/C 78.1, and C/C 76.6; p =&#x2009;0.037), and more frequent behavioral disturbances (A/A 16.7%, A/C 24.4%, and C/C 27.7%; p =&#x2009;0.045). Thinner left inferior temporal and right fusiform cortex were associated with the UNC13A single nucleotide polymorphism (SNP; p =&#x2009;0.045 and p =&#x2009;0.036).</AbstractText><AbstractText Label="INTERPRETATION">Phenotypical distinctions associated with UNC13A make it an important factor to take into account in clinical trial design, studies on cognition and behavior, and prognostic counseling. ANN NEUROL 2020;88:796-806.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Harold H G</ForeName><Initials>HHG</Initials><Identifier Source="ORCID">0000-0002-2981-9680</Identifier><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westeneng</LastName><ForeName>Henk-Jan</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Burgh</LastName><ForeName>Hannelore K</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Es</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakker</LastName><ForeName>Leonhard A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence for Rehabilitation Medicine, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University and De Hoogstraat Rehabilitation, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Veenhuijzen</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Eijk</LastName><ForeName>Kristel R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Eijk</LastName><ForeName>Ruben P A</ForeName><Initials>RPA</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biostatistics and Research Support, Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veldink</LastName><ForeName>Jan H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C485548">UNC13B protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors report no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32627229</ArticleId><ArticleId IdType="pmc">PMC7540607</ArticleId><ArticleId IdType="doi">10.1002/ana.25841</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet 2017;390:2084&#x2013;2098.</Citation><ArticleIdList><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld J. Rethinking amyotrophic lateral sclerosis. Mayo Clin Proc 2018;93:1543&#x2013;1545.</Citation><ArticleIdList><ArticleId IdType="pubmed">30392539</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol 2014;13:1127&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316019</ArticleId></ArticleIdList></Reference><Reference><Citation>Su XW, Broach JR, Connor JR, et al. Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research. Muscle Nerve 2014;49:786&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pubmed">24488689</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, van Blitterswijk M, Huisman MHB, et al. Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases. Neurology 2012;79:878&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pubmed">22843265</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Elamin M, Bede P, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population&#x2010;based cohort study. Lancet Neurol 2012;11:232&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315021</ArticleId><ArticleId IdType="pubmed">22305801</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Borghero G, Restagno G, et al. Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Brain 2012;135:784&#x2013;793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286333</ArticleId><ArticleId IdType="pubmed">22366794</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P, Bokde ALW, Byrne S, et al. Multiparametric MRI study of ALS stratified for the C9orf72 genotype. Neurology 2013;81:361&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3772833</ArticleId><ArticleId IdType="pubmed">23771489</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H&#x2010;J, Walhout R, Straathof M, et al. Widespread structural brain involvement in ALS is not limited to the C9orf72 repeat expansion. J Neurol Neurosurg Psychiatry 2016;87:1354&#x2013;1360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5136726</ArticleId><ArticleId IdType="pubmed">27756805</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Veldink JH, Saris CGJ, et al. Genome&#x2010;wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet 2009;41:1083&#x2013;1087.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734901</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekstra FP, Van Deerlin VM, van Swieten JC, et al. C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: a genome&#x2010;wide meta&#x2010;analysis. Ann Neurol 2014;76:120&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4137231</ArticleId><ArticleId IdType="pubmed">24931836</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Jones AR, Sproviero W, et al. Meta&#x2010;analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology 2017;89:1915&#x2013;1922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5664299</ArticleId><ArticleId IdType="pubmed">28978660</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekstra FP, van Vught PWJ, van Rheenen W, et al. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol Aging 2012;33:630.e3&#x2013;630.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22118904</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mora G, Restagno G, et al. UNC13A influences survival in Italian amyotrophic lateral sclerosis patients: a population&#x2010;based study. Neurobiol Aging 2013;34:357.e1&#x2013;357.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3483408</ArticleId><ArticleId IdType="pubmed">22921269</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal&#x2010;Taboada JM, Lopez&#x2010;Lopez A, Salvado M, et al. UNC13A confers risk for sporadic ALS and influences survival in a Spanish cohort. J Neurol 2015;262:2285&#x2013;2292.</Citation><ArticleIdList><ArticleId IdType="pubmed">26162714</ArticleId></ArticleIdList></Reference><Reference><Citation>Placek K, Baer GM, Elman L, et al. UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis. Neurobiol Aging 2019;73:190&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6251755</ArticleId><ArticleId IdType="pubmed">30368160</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS&#x2010;R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci 1999;169:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRS&#x2010;R at time of diagnosis predicts survival time in ALS. Neurology 2006;66:265&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Newton J, Niven E, et al. Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Front Degener 2014;15:9&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">23781974</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker LA, Schr&#xf6;der CD, Spreij LA, et al. Derivation of norms for the Dutch version of the Edinburgh cognitive and behavioral ALS screen. Amyotroph Lateral Scler Front Degener 2019;20:19&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">30314420</ArticleId></ArticleIdList></Reference><Reference><Citation>Raaphorst J, Beeldman E, Schmand B, et al. The ALS&#x2010;FTD&#x2010;Q: a new screening tool for behavioral disturbances in ALS. Neurology 2012;79:1377&#x2013;1383.</Citation><ArticleIdList><ArticleId IdType="pubmed">22972650</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis &#x2010; frontotemporal spectrum disorder (ALS&#x2010;FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Front Degener 2017;18:153&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B. FreeSurfer. Neuroimage 2012;62:774&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3685476</ArticleId><ArticleId IdType="pubmed">22248573</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, S&#xe9;gonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006;31:968&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori S, Crain BJ, Chacko VP, van Zijl PCM. Three&#x2010;dimensional tracking of axonal projections in the brain by magnetic resonance imaging. Ann Neurol 1999;45:265&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">9989633</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt R, Verstraete E, de Reus MA, et al. Correlation between structural and functional connectivity impairment in amyotrophic lateral sclerosis. Hum Brain Mapp 2014;35:4386&#x2013;4395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4207190</ArticleId><ArticleId IdType="pubmed">24604691</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin DY, Wei LJ. The robust inference for the cox proportional hazards model. J Am Stat Assoc 1989;84:1074&#x2013;1078.</Citation></Reference><Reference><Citation>Westeneng H&#x2010;J, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol 2018;17:423&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox J. Effect displays in R for generalised linear models. J Stat Softw 2003;8:1&#x2013;9.</Citation></Reference><Reference><Citation>Zalesky A, Fornito A, Bullmore ET. Network&#x2010;based statistic: identifying differences in brain networks. Neuroimage 2010;53:1197&#x2013;1207.</Citation><ArticleIdList><ArticleId IdType="pubmed">20600983</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Przybelski SA, Weigand SD, et al. Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain 2009;132:2932&#x2013;2946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768663</ArticleId><ArticleId IdType="pubmed">19762452</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoi D, Atsuta N, Watanabe H, et al. Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis. J Neurol 2016;263:1129&#x2013;1136.</Citation><ArticleIdList><ArticleId IdType="pubmed">27083563</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, Shatunov A, Dekker AM, et al. Genome&#x2010;wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet 2016;48:1043&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A, Kenna KP, Renton AE, et al. Genome&#x2010;wide analyses identify KIF5A as a novel ALSGene. Neuron 2018;97:1268&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Eijkemans MJC, Nikolakopoulos S, et al. Pharmacogenetic interactions in amyotrophic lateral sclerosis: a step closer to a cure? Pharmacogenomics J 2020;20:220&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">31624333</ArticleId></ArticleIdList></Reference><Reference><Citation>Dittman JS. Unc13: a multifunctional synaptic marvel. Curr Opin Neurobiol 2019;57:17&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6629506</ArticleId><ArticleId IdType="pubmed">30690332</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mazzini L, D'Alfonso S, et al. The multistep hypothesis of ALS revisited: the role of genetic mutations. Neurology 2018;91:e635&#x2013;e642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6105040</ArticleId><ArticleId IdType="pubmed">30045958</ArticleId></ArticleIdList></Reference><Reference><Citation>Montuschi A, Iazzolino B, Calvo A, et al. Cognitive correlates in amyotrophic lateral sclerosis: a population&#x2010;based study in Italy. J Neurol Neurosurg Psychiatry 2015;86:168&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">24769471</ArticleId></ArticleIdList></Reference><Reference><Citation>Strutt AM, Palcic J, Wager JG, et al. Cognition, behavior, and respiratory function in amyotrophic lateral sclerosis. ISRN Neurol 2012;2012:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3407622</ArticleId><ArticleId IdType="pubmed">22852095</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeldman E, Raaphorst J, Twennaar MK, et al. The cognitive profile of ALS: a systematic review and meta&#x2010;analysis update. J Neurol Neurosurg Psychiatry 2016;87:611&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">26283685</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP&#x2010;43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013;74:20&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Brettschneider J, Ludolph AC, et al. Amyotrophic lateral sclerosis&#x2014;a model of corticofugal axonal spread. Nat Rev Neurol 2013;9:708&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3943211</ArticleId><ArticleId IdType="pubmed">24217521</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>